Your browser doesn't support javascript.
loading
Mostrar: 20 | 50 | 100
Resultados 1 - 11 de 11
Filtrar
Mais filtros










Intervalo de ano de publicação
1.
Neurol Res ; 38(4): 294-300, 2016 Apr.
Artigo em Inglês | MEDLINE | ID: mdl-27098232

RESUMO

OBJECTIVES: Potassium channels participate in cellular and molecular signalling pathways regulating the life and death of neurons. In this study, effect of pretreatment with potassium channel blockers of 4-aminopyridine (4-AP) and tetraethylammonium (TEA) on the behavioural symptoms of 6-hydroxydopamine (6-OHDA)-induced Parkinsonism was evaluated. METHODS: 6-OHDA was injected into right striatum of adult male Wistar rats using stereotaxic surgery. Severity of 6-OHDA-induced Parkinsonism was assessed by conventional behavioural tests. 4-AP and TEA were injected twice per day intraperitoneally, before 6-OHDA injection to 15 days after that. Also, malondialdehyde (MDA) concentration as a marker of oxidative stress was measured in rat sera. RESULTS: Pretreatment with 4-AP (0.5 and 1 mg/kg) and TEA (2 and 5 mg/kg) attenuated significantly behavioural symptoms of 6-OHDA-induced Parkinsonism. Application of both 4-AP and TEA together was more effective than the effect of each one of these blockers alone. 6-OHDA increased MDA concentration but pretreatment with 4-AP prevented of 6-OHDA-induced increase in MDA. On the other hand, pretreatment with TEA and combination of TEA and 4-AP could not prevent of 6-OHDA-induced oxidative stress. DISCUSSION: Since severity of behavioural symptoms of 6-OHDA-induced Parkinsonism is correlated to the degree of nigral dopaminergic cell death, we suggest that antiparkinsonism effect of TEA and 4-AP was mediated by their neuroprotective effect. Because, both Parkinsonism in rat and PD in human, the main pathophysiological hallmark, is neurodegeneration of dopaminergic neurons in substantia nigra, we suggest doing clinical trials for evaluation of effectiveness of 4-AP and TEA in slowing down of PD progress.


Assuntos
4-Aminopiridina/uso terapêutico , Transtornos Mentais/etiologia , Transtornos Mentais/prevenção & controle , Transtornos Parkinsonianos/complicações , Bloqueadores dos Canais de Potássio/uso terapêutico , Tetraetilamônio/uso terapêutico , Adrenérgicos , Animais , Apomorfina/farmacologia , Corpo Estriado/efeitos dos fármacos , Modelos Animais de Doenças , Relação Dose-Resposta a Droga , Esquema de Medicação , Lateralidade Funcional/efeitos dos fármacos , Masculino , Atividade Motora/efeitos dos fármacos , Oxidopamina/toxicidade , Transtornos Parkinsonianos/sangue , Transtornos Parkinsonianos/induzido quimicamente , Equilíbrio Postural/efeitos dos fármacos , Ratos , Ratos Wistar , Tiazolidinedionas/sangue
2.
J. bras. med ; 102(1)jan.-fev. 2014.
Artigo em Português | LILACS | ID: lil-712208

RESUMO

A síndrome de fadiga crônica (SFC) é uma condição clínica que, apesar de muito prevalente, tem tratamento controverso. A suplementação com substratos como glutamina e vitaminas pode atuar como adjuvante terapêutico. Os autores descrevem um medicamento que pode atender essa finalidade, composto por glutamina 200mg, glutamato de cálcio 250mg, cloridrato de piridoxina 20mg e fosfato de ditetraetilamônio 6mg. São descritas também as ações de cada um dos componentes, e como podem auxiliar na terapêutica da SFC e em períodos de convalescença em diversas condições.


The chronic fatigue syndrome (CFS) is a clinical condition which, although highly prevalent, treatment is controversial and supplementation of substrates such as glutamine and vitamins can act as therapeutic adjuvant. A drug composition that can serve this purpose, the composition is glutamine 200mg, 250mg calcium glutamate, 20mg pyridoxine hydrochloride and phosphate ditetraetilammonium 6mg is described. Also described the actions of each component and how they can assist in the treatment of CFS and in periods of convalescence from various other conditions described.


Assuntos
Humanos , Masculino , Feminino , Síndrome de Fadiga Crônica/dietoterapia , Síndrome de Fadiga Crônica/terapia , Convalescença , Vitaminas na Dieta , Glutamatos/uso terapêutico , Glutamina/uso terapêutico , Minerais/uso terapêutico , Piridoxina/uso terapêutico , Suplementos Nutricionais , Tetraetilamônio/uso terapêutico
3.
J Trace Elem Med Biol ; 26(4): 279-84, 2012 Oct.
Artigo em Inglês | MEDLINE | ID: mdl-22677540

RESUMO

In this study, the ability of the chelating agent monensic acid (administered as the tetraethylammonium salt) to reduce the cadmium (Cd) concentration in the kidneys, liver, heart, lungs, spleen and testes of Cd-intoxicated mice was investigated. Chelation therapy with the tetraethylammonium salt of monensic acid led to a significant decrease of the Cd concentration in all of the organs of the Cd-treated mice. This effect varied from 50% in the kidneys to 90% in the hearts of the sacrificed animals (compared to the Cd-treated controls). No redistribution of the toxic metal ions to the brain of the animals as a result of the detoxification with the chelating agent was observed. The detoxification of the animals with the antibiotic salt did not perturb the endogenous levels of copper (Cu) or zinc (Zn). The tetraethylammonium salt of monensic acid significantly ameliorated the Cd-induced total iron (Fe) depletion in the liver and spleen of Cd-treated mice. It also restored to control levels the values of transferrin-bound Fe and the total iron binding capacity (TIBC) of the plasma. These results imply that the tetraethylammonium salt of monensic acid could be an efficient antidote in cases of Cd-intoxication.


Assuntos
Cádmio/toxicidade , Furanos/uso terapêutico , Ácidos Pentanoicos/uso terapêutico , Tetraetilamônio/uso terapêutico , Animais , Intoxicação por Cádmio/tratamento farmacológico , Masculino , Camundongos , Camundongos Endogâmicos ICR
4.
Naunyn Schmiedebergs Arch Pharmacol ; 384(2): 147-55, 2011 Aug.
Artigo em Inglês | MEDLINE | ID: mdl-21630039

RESUMO

Hirschsprung's disease is the congenital absence of generating the peristaltic contractions transmitting from the proximal colon to rectum. We previously have found that tetraethylammonium (TEA), the nonselective Ca(2+)-activated K(+) channel blocker, increases the maximal contractile force and the amplitude of the contraction in rat duodenum. The present study is to test the effect of TEA on motility of colon and rectum from rats and Hirschsprung's disease patients in vitro, in order to find an alternative method to improve the syndrome of Hirschsprung's disease. The rectal and colonic motility was recorded by a tension transducer connected to a biology function experiment system. Histology was analyzed with standard hematoxylin and eosin staining. TEA (1, 3, and 5 mM) significantly increased the amplitude and frequency of contractility of colon and rectum from rats in longitudinal and circular direction. TEA at 5 and 15 mM concentrations showed no effect on histology of colon and rectum from rats that were administered locally with TEA into colon lumen from anus for 10 days. TEA at 15 mM increased the amplitude and frequency of contractions of the colon and rectum from Hirschsprung's disease patients. Our data showed that TEA increased the contractility of colon and rectum from rats and Hirschsprung's disease patients in vitro, suggesting that local administration of TEA in colon or rectum lumen might be an alternative method to ameliorate the syndrome of Hirschsprung's disease patients who are not cured completely by surgery or not suitable for surgery.


Assuntos
Colo/efeitos dos fármacos , Motilidade Gastrointestinal/efeitos dos fármacos , Bloqueadores dos Canais de Potássio/farmacologia , Reto/efeitos dos fármacos , Tetraetilamônio/farmacologia , Animais , Pré-Escolar , Colo/patologia , Doença de Hirschsprung/tratamento farmacológico , Doença de Hirschsprung/patologia , Doença de Hirschsprung/fisiopatologia , Humanos , Masculino , Contração Muscular/efeitos dos fármacos , Músculo Liso/efeitos dos fármacos , Músculo Liso/patologia , Técnicas de Cultura de Órgãos , Bloqueadores dos Canais de Potássio/uso terapêutico , Ratos , Ratos Wistar , Reto/patologia , Tetraetilamônio/uso terapêutico
5.
Behav Brain Res ; 223(1): 70-4, 2011 Sep 30.
Artigo em Inglês | MEDLINE | ID: mdl-21540059

RESUMO

Parkinson's disease (PD) is a progressive neurodegenerative disorder characterizing by degeneration of dopaminergic neurons in the nigrostriatal pathway. The discovery of levodopa revolutionized the treatment of PD however, after several years of treatment most patients develop involuntary movements which significantly impair the quality of life. 4-Aminopyridine (4-AP) and tetraethylammonium (TEA) are wide-spectrum potassium channel blockers which based on the animal model studies and clinical trials have beneficial effects in treatment of several neurological disorders such as ataxia, Alzheimer disease and multiple sclerosis. Current study investigates effect of these blockers in the treatment of 6-hydroxydopamine (6-OHDA)-induced Parkinsonism. After surgical injection of 6-OHDA into medial forebrain bundle, behavioral tests were performed in the 2nd and 3rd weeks post-surgery. Only animals which showed more than 100 apomorphine-induced rotations/1h in the 3rd week were selected for evaluation of the blocker effects. Statistical analysis of results from rotational test shows that application of high dose of 4-AP (1mg/kg) and moderate dose of TEA (2mg/kg) attenuate behavioral symptoms of the Parkinsonism while high dose of TEA (5mg/kg) and application both 4-AP and TEA exacerbates these symptoms. Results from elevated body swing test confirmed the effects of TEA but not 4-AP on the rotational test. However, experiments performed on the partial Parkinsonian rats show that application of high dose of TEA attenuates apomorphine-induced rotational asymmetry significantly. Our findings indicating TEA and 4-AP could have significant effects in attenuation of PD symptoms but these effects are sensitive to dose and degree of severity of PD.


Assuntos
4-Aminopiridina/uso terapêutico , Comportamento Animal/efeitos dos fármacos , Oxidopamina , Doença de Parkinson Secundária/induzido quimicamente , Doença de Parkinson Secundária/tratamento farmacológico , Bloqueadores dos Canais de Potássio/uso terapêutico , Tetraetilamônio/uso terapêutico , 4-Aminopiridina/farmacologia , Animais , Apomorfina/antagonistas & inibidores , Apomorfina/farmacologia , Modelos Animais de Doenças , Interações Medicamentosas , Masculino , Feixe Prosencefálico Mediano/efeitos dos fármacos , Microinjeções , Bloqueadores dos Canais de Potássio/farmacologia , Ratos , Ratos Wistar , Tetraetilamônio/farmacologia
6.
Br J Pharmacol ; 163(6): 1289-301, 2011 Jul.
Artigo em Inglês | MEDLINE | ID: mdl-21410460

RESUMO

BACKGROUND AND PURPOSE: There is increasing evidence that potassium channels are involved in the cardiovascular dysfunction of sepsis. This evidence was obtained after the systemic inflammation, cardiovascular dysfunction and organ damage had developed. Here we have studied the consequences of early interference with potassium channels on development of sepsis. EXPERIMENTAL APPROACH: Sepsis was induced by caecal ligation and puncture (CLP) or sham surgery in Wistar rats. Four hours after surgery, animals received tetraethylammonium (TEA; a non-selective potassium channel blocker) or glibenclamide (a selective ATP-sensitive potassium channel blocker). Twenty-four hours after surgery, inflammatory, biochemical, haemodynamic parameters and survival were evaluated. KEY RESULTS: Sepsis significantly increased plasma NO(x) levels, expression of inducible nitric oxide synthase (NOS-2) protein in lung and thigh skeletal muscle, lung myeloperoxidase, urea, creatinine and lactate levels, TNF-α and IL-1ß, hypotension and hyporesponsiveness to phenylephrine and hyperglycemia followed by hypoglycemia. TEA injected 4 h after surgery attenuated the increased NOS-2 expression, reduced plasma NO(x) , lung myeloperoxidase activity, levels of TNF-α and IL-1ß, urea, creatinine and lactate levels, prevented development of hypotension and hyporesponsiveness to phenylephrine, the alterations in plasma glucose and reduced late mortality by 50%. Glibenclamide did not improve any of the measured parameters and increased mortality rate, probably due to worsening the hypoglycemic phase of sepsis. CONCLUSIONS AND IMPLICATIONS: Early blockade of TEA-sensitive (but not the ATP-sensitive subtype) potassium channels reduced organ damage and mortality in experimental sepsis. This beneficial effect seems to be, at least in part, due to reduction in NOS-2 expression.


Assuntos
Doenças Cardiovasculares/tratamento farmacológico , Glibureto/uso terapêutico , Bloqueadores dos Canais de Potássio/uso terapêutico , Sepse/complicações , Tetraetilamônio/uso terapêutico , Animais , Pressão Sanguínea , Feminino , Regulação Enzimológica da Expressão Gênica , Frequência Cardíaca , Longevidade , Pulmão/efeitos dos fármacos , Pulmão/metabolismo , Músculo Esquelético/efeitos dos fármacos , Músculo Esquelético/metabolismo , Óxido Nítrico Sintase Tipo II/genética , Óxido Nítrico Sintase Tipo II/metabolismo , Ratos , Ratos Wistar , Vasoconstritores/farmacologia
7.
Shock ; 35(5): 485-91, 2011 May.
Artigo em Inglês | MEDLINE | ID: mdl-21330953

RESUMO

Nitric oxide-mediated activation of large conductance calcium-activated potassium (BK) channels is considered an important underlying mechanism of sepsis-induced hypotension. Indeed, the nonselective K-channel inhibitor, tetraethylammonium chloride (TEA), has been proposed as a potential treatment to raise blood pressure in septic shock by virtue of its ability to inhibit BK channels. As experimental evidence has so far relied on pharmacological inhibition, we examined the effects of channel deletion using BKα subunit knockout (α, Slo) mice in two mouse models of polymicrobial sepsis, namely, intraperitoneal fecal slurry and cecal ligation and puncture. Comparison was made against TEA treatment in wild-type (WT) mice. Following slurry, BKα and WT mice developed similar degrees of hypotension over 10 h with no difference in cardiac output as assessed by echocardiography between groups. Tetraethylammonium chloride raised blood pressure significantly in septic WT mice, but had no effect on survival. However, following cecal ligation and puncture, a significantly reduced survival was seen in both BKα mice and (high-dose) TEA-treated WT mice compared with untreated WT animals. In conclusion, the BK channel does not appear to be integral to sepsis-induced hypotension but does affect survival through other mechanisms. The pressor effect of TEA may be related to effects on other potassium channels.


Assuntos
Hipotensão/genética , Subunidades alfa do Canal de Potássio Ativado por Cálcio de Condutância Alta/deficiência , Sepse/microbiologia , Sepse/mortalidade , Animais , Pressão Sanguínea/efeitos dos fármacos , Pressão Sanguínea/genética , Genótipo , Hipotensão/tratamento farmacológico , Subunidades alfa do Canal de Potássio Ativado por Cálcio de Condutância Alta/genética , Masculino , Camundongos , Camundongos Knockout , Bloqueadores dos Canais de Potássio/uso terapêutico , Reação em Cadeia da Polimerase Via Transcriptase Reversa , Sepse/tratamento farmacológico , Sepse/genética , Tetraetilamônio/uso terapêutico
8.
Chemotherapy ; 55(5): 372-80, 2009.
Artigo em Inglês | MEDLINE | ID: mdl-19707016

RESUMO

BACKGROUND: Potassium channel blockers have been shown to possess antitumor properties, but the role of apoptosis remains to be clarified. In this study, we investigated the antiproliferative effect of tetraethylammonium (TEA), a nonspecific potassium channel blocker, in rat C6 and 9L glioma cells. METHODS: Cytotoxicity was evaluated by MTT assay. Apoptosis was detected by TUNEL and annexin V-FITC/propidium iodide assays. Protein levels were determined by Western blot analysis. Intracellular reactive oxygen species (ROS) levels were assessed flow cytometrically. RESULTS: TEA (2-60 mM) significantly inhibited the proliferation of C6 and 9L glioma cells. In addition, increased cell apoptosis was confirmed after treatment with 40 mM TEA. Apoptosis was associated with a dramatic increase in ROS levels and altered Bcl-2/Bax protein balance. CONCLUSION: TEA can inhibit proliferation and induce apoptosis in both cell lines; therefore, it might be associated with the increase in intracellular ROS production.


Assuntos
Antineoplásicos/uso terapêutico , Glioma/tratamento farmacológico , Bloqueadores dos Canais de Potássio/uso terapêutico , Espécies Reativas de Oxigênio/metabolismo , Tetraetilamônio/uso terapêutico , Animais , Apoptose , Linhagem Celular Tumoral , Sobrevivência Celular/efeitos dos fármacos , Glioma/metabolismo , Ratos
9.
Eur J Pharmacol ; 556(1-3): 215-22, 2007 Feb 05.
Artigo em Inglês | MEDLINE | ID: mdl-17182029

RESUMO

Intestinal ischemia and reperfusion injury is dependent on the recruitment and activation of neutrophils. Glibenclamide, an ATP-sensitive potassium channel (K(ATP)) blocker, has been shown to suppress neutrophil migration and chemotaxis during acute inflammatory responses by a mechanism dependent on its K(ATP) channel blocking activity. In the present study, we evaluated whether the treatment with glibenclamide prevented local, remote and systemic injury following reperfusion of the ischemic superior mesenteric artery in rats. The artery was made ischemic for a period of 30 or 120 min followed by 30 (mild I/R) or 120 (severe I/R) min of reperfusion, respectively. Glibenclamide (0.8 to 20 mg/kg) or vehicle was administered subcutaneously 40 min prior to the reperfusion. Glibenclamide dose-dependently inhibited the reperfusion-associated increase in vascular permeability and neutrophil accumulation in mild I/R. In the severe injury model, glibenclamide inhibited inflammatory parameters, as assessed by Evans blue extravasation, neutrophil influx and haemoglobin content, and the increase in TNF-alpha (tumor necrose factor-alpha) and IL (interleukin)-6 levels in the intestine and lung. The drug did not affect the increase in IL-1beta and IL-10 levels. TEA, a nonselective potassium channel blocker, also inhibited reperfusion injury in both intestine and lungs of animals submitted to mild and severe I/R. Our experiments suggest a role for K(ATP) channels in mediating neutrophil influx and consequent reperfusion-associated injury in rats. The lack of effect of these drugs on the reperfusion-associated hypotension and lethality may limit their usefulness after severe reperfusion injury.


Assuntos
Trifosfato de Adenosina/fisiologia , Glibureto/uso terapêutico , Intestinos/irrigação sanguínea , Isquemia/prevenção & controle , Bloqueadores dos Canais de Potássio/uso terapêutico , Traumatismo por Reperfusão/prevenção & controle , Animais , Permeabilidade Capilar/efeitos dos fármacos , Quimiotaxia de Leucócito/efeitos dos fármacos , Citocinas/biossíntese , Glibureto/administração & dosagem , Intestinos/patologia , Ativação do Canal Iônico , Isquemia/patologia , Isquemia/fisiopatologia , Masculino , Artéria Mesentérica Superior/fisiopatologia , Minoxidil/uso terapêutico , Neutrófilos/efeitos dos fármacos , Neutrófilos/fisiologia , Bloqueadores dos Canais de Potássio/administração & dosagem , Ratos , Ratos Wistar , Traumatismo por Reperfusão/mortalidade , Traumatismo por Reperfusão/patologia , Tetraetilamônio/uso terapêutico
10.
Hypertens Res ; 29(12): 1021-7, 2006 Dec.
Artigo em Inglês | MEDLINE | ID: mdl-17378375

RESUMO

Hypertension due to chronic inhibition of NO synthase (NOS) by Nomega-nitro-L-arginine methyl ester (L-NAME) administration is characterized by both impaired NO-dependent vasodilation and enhanced sympathetic vasoconstriction. The aim of our study was to evaluate changes in the participation of major vasoactive systems in L-NAME-treated rats which were subjected to simultaneous antihypertensive (captopril) or antioxidant (N-acetylcysteine, NAC) treatment. Three-month-old Wistar males treated with L-NAME (60 mg/kg/day) for 5 weeks were compared to rats in which L-NAME treatment was combined with simultaneous chronic administration of captopril or NAC. Basal blood pressure (BP) and its acute responses to consecutive i.v. injections of captopril (10 mg/kg), pentolinium (5 mg/kg), L-NAME (30 mg/kg), tetraethylammonium (TEA, 16 mg/kg) and nitroprusside (NP, 20 microg/kg) were determined in conscious rats at the end of the study. The development of L-NAME hypertension was prevented by captopril treatment, whereas NAC treatment caused only a moderate BP reduction. Captopril treatment normalized the sympathetic BP component and significantly reduced residual BP (measured at full NP-induced vasodilation). In contrast, chronic NAC treatment did not modify the sympathetic BP component or residual BP, but significantly enhanced NO-dependent vasodilation. Neither captopril nor NAC treatment influenced the compensatory increase of TEA-sensitive vasodilation mediated by endothelium-derived hyperpolarizing factor in L-NAME-treated rats. Chronic captopril treatment prevented L-NAME hypertension by lowering of sympathetic tone, whereas chronic NAC treatment attenuated L-NAME hypertension by reduction in the vasodilator deficit due to enhanced NO-dependent vasodilation.


Assuntos
Acetilcisteína/uso terapêutico , Anti-Hipertensivos/uso terapêutico , Captopril/uso terapêutico , Hipertensão/prevenção & controle , Acetilcisteína/farmacologia , Animais , Anti-Hipertensivos/farmacologia , Pressão Sanguínea/efeitos dos fármacos , Captopril/farmacologia , Hipertensão/induzido quimicamente , Masculino , NG-Nitroarginina Metil Éster/antagonistas & inibidores , NG-Nitroarginina Metil Éster/farmacologia , Nitroprussiato/farmacologia , Nitroprussiato/uso terapêutico , Tartarato de Pentolínio/farmacologia , Tartarato de Pentolínio/uso terapêutico , Ratos , Ratos Wistar , Tetraetilamônio/farmacologia , Tetraetilamônio/uso terapêutico
11.
J Am Coll Cardiol ; 38(5): 1554-63, 2001 Nov 01.
Artigo em Inglês | MEDLINE | ID: mdl-11691539

RESUMO

OBJECTIVES: We sought to determine whether potassium (K(+)) channel blockers (KBs) can activate extracellular signal-regulated kinase (ERK) and to characterize the upstream signals leading to ERK activation in cardiomyocytes. BACKGROUND: Because KBs attenuate K(+) outward current, they may possibly prolong the duration of action potentials, leading to an increase in calcium (Ca(2+)) transient ([Ca(2+)](i)) in cardiomyocytes. Elevation of intracellular Ca(2+) levels can trigger various signaling events. Influx of Ca(2+) through L-type Ca(2+) channels after membrane depolarization induced activation of MEK and ERK through activation of Ras in neurons. Although KBs are frequently used to treat cardiac arrhythmias, their effect on signaling pathways remains unknown. METHODS: Primary cultured rat cardiomyocytes were stimulated with four different KBs-4-aminopyridine (4-AP), E-4031, tetra-ethylammonium and quinidine-and phosphorylation of ERK, proline-rich tyrosine kinase 2 (Pyk2) and epidermal growth factor receptor (EGFR) was detected. Action potentials were recorded by use of a conventional microelectrode. (Ca(2+))(i) was monitored by the fluorescent calcium indicator Fluo-4. RESULTS: E-4031, 4-AP, tetra-ethylammonium and quinidine induced phosphorylation of ERK. 4-Aminopyridine prolonged the duration of action potentials by 37% and increased (Ca(2+))(i) by 52% at 1 mmol/l. Pre-incubation of ethyleneglycoltetraacetic acid, 1,2-bis(2-aminophenoxy)-ethane-N,N,N',N'-tetraacetic acid tetrakis and diltiazem completely blocked this phosphorylation, whereas flufenamic acid and benzamil did not. 4-Aminopyridine induced tyrosine phosphorylation of Pyk2 and EGFR, which peaked at 5 and 10 min, respectively. Cytochalasin D, AG1478 and dominant-negative EGFR strongly inhibited the phosphorylation of ERK, whereas calphostin C, calmidazolium and KN62 did not. CONCLUSIONS: These findings indicate that KBs induce ERK activation, which starts with Ca(2+) entry through the L-type Ca(2+) channel in cardiomyocytes, and that EGFR and Pyk2 are involved in this activation.


Assuntos
4-Aminopiridina/farmacologia , Antiarrítmicos/farmacologia , Canais de Cálcio Tipo L/efeitos dos fármacos , Receptores ErbB/efeitos dos fármacos , Proteínas Quinases Ativadas por Mitógeno/efeitos dos fármacos , Miocárdio/citologia , Piperidinas/farmacologia , Bloqueadores dos Canais de Potássio/farmacologia , Proteínas Tirosina Quinases/efeitos dos fármacos , Piridinas/farmacologia , Quinidina/farmacologia , Tetraetilamônio/farmacologia , 4-Aminopiridina/uso terapêutico , Potenciais de Ação/efeitos dos fármacos , Animais , Antiarrítmicos/uso terapêutico , Arritmias Cardíacas/tratamento farmacológico , Arritmias Cardíacas/metabolismo , Arritmias Cardíacas/fisiopatologia , Canais de Cálcio Tipo L/fisiologia , Células Cultivadas , Citocalasina D/farmacologia , Avaliação Pré-Clínica de Medicamentos , Receptores ErbB/fisiologia , Quinase 2 de Adesão Focal , Proteínas Quinases Ativadas por Mitógeno/fisiologia , Fosforilação , Piperidinas/uso terapêutico , Bloqueadores dos Canais de Potássio/uso terapêutico , Proteínas Tirosina Quinases/fisiologia , Piridinas/uso terapêutico , Quinazolinas , Quinidina/uso terapêutico , Ratos , Ratos Wistar , Tetraetilamônio/uso terapêutico , Fatores de Tempo , Tirfostinas/farmacologia
SELEÇÃO DE REFERÊNCIAS
DETALHE DA PESQUISA
...